References
- Agarwala AK, Perkins SM, Abonour R, Brames MJ, Einhorn LH. (2011). Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol34: 286–288.
- Aguiar PN, Jr., Tadokoro H, da Silva GF, Landgraf MM, Noia Barreto CM, Filardi BA, Lopes GL, Jr., Oliveira P, de Mello RA. (2016). Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. Future Oncol12: 2755–2764.
- Al-Sweedan SA, Khabour O, Isam R. (2012). Genotoxicity assessment in patients with thalassemia minor. Mutat Res744: 167–171.
- Alzoubi K, Khabour O, Hussain N, Al-Azzam S, Mhaidat N. (2012). Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone. Mutat Res748: 48–51.
- Alzoubi K, Khabour O, Khader M, Mhaidat N, Al-Azzam S. (2014). Evaluation of vitamin B12 effects on DNA damage induced by paclitaxel. Drug Chem Toxicol37: 276–280.
- Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R. (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst99: 847–857.
- Azab M, Khabour OF, Al-Omari L, Alzubi MA, Alzoubi K. (2009). Effect of every-other-day fasting on spontaneous chromosomal damage in rat’s bone-marrow cells. J Toxicol Environ Health A72: 295–300.
- Azab M, Khabour OF, Alzoubi KH, Hawamdeh H, Quttina M, Nassar L. (2017). Assessment of genotoxicity of pyrethrin in cultured human lymphocytes. Drug Chem Toxicol40: 251–255.
- Brozovic G, Orsolic N, Knezevic F, Horvat Knezevic A, Benkovic V, Sakic K, Hrgovic Z, Bendelja K, Fassbender WJ. (2009). Genotoxicity and cytotoxicity of cisplatin treatment combined with anaesthetics on EAT cells in vivo. Onkologie32: 337–343.
- Bruning A, Mylonas I. (2011). New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. Arch Gynecol Obstet283: 1087–1096.
- Castrellon AB, Pidhorecky I, Valero V, Raez LE. (2017). The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev11: 324.
- Clare G. (2012). The in vitro mammalian chromosome aberration test. Methods Mol Biol817: 69–91.
- Cruet-Hennequart S, Villalan S, Kaczmarczyk A, O’Meara E, Sokol AM, Carty MP. (2009). Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle (Georgetown, Tex)8: 3039–3050.
- de Castria TB, da Silva EM, Gois AF, Riera R. (2013). Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev CD009256.10.1002/14651858.CD009256.pub223949842
- Desai B, Gadhia P. (2012). Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents. Neoplasma59: 463–468.
- Duan X, He C, Kron SJ, Lin W. (2016). Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol8: 776–791.
- Duffull SB, Robinson BA. (1997). Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet33: 161–183.
- Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. (2016). Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev44: 42–50.
- Ghosh P, Roy SS, Chakraborty P, Ghosh S, Bhattacharya S. (2013). Effects of organoselenium compound 2-(5-selenocyanato-pentyl)-benzo[de]isoquinoline 1,3-dione on cisplatin induced nephrotoxicity and genotoxicity: an investigation of the influence of the compound on oxidative stress and antioxidant enzyme system. Biometals26: 61–73.
- Gonzalez Cid M, Mudry M, Larripa I. (1995). Chromosome damage induced by carboplatin (CBDCA). Toxicol Lett76: 97–103.
- Hah SS, Stivers KM, de Vere White RW, Henderson PT. (2006). Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol19: 622–626.
- Hongo A, Seki S, Akiyama K, Kudo T. (1994). A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Int J Biochem26: 1009–1016.
- Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. (2004). Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol22: 3860–3867.
- Chibber R, Ord MJ. (1989). The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin. Eur J Cancer Clin Oncol25: 27–33.
- Khabour OF, Alsatari ES, Azab M, Alzoubi KH, Sadiq MF. (2011). Assessment of genotoxicity of waterpipe and cigarette smoking in lymphocytes using the sister-chromatid exchange assay: a comparative study. Environ Mol Mutagen52: 224–228.
- Khabour OF, Alzoubi KH, Mfady DS, Alasseiri M, Hasheesh TF. (2014). Tempol protects human lymphocytes from genotoxicity induced by cisplatin. Int J Clin Exp Med7: 982–988.
- Kralovanszky J, Prajda N, Kerpel-Fronius S, Gal F, Kiss F. (1988). Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP). Cancer Chemother Pharmacol21: 40–44.
- Mhaidat NM, Alzoubi KH, Khabour OF, Alawneh KZ, Raffee LA, Alsatari ES, Hussein EI, Bani-Hani KE. (2016). Assessment of genotoxicity of vincristine, vinblastine and vinorelbine in human cultured lymphocytes: a comparative study. Balkan J Med Genet19: 13–20.
- Moncharmont C, Auberdiac P, Melis A, Afqir S, Pacaut C, Chargari C, Merrouche Y, Magne N. (2011). [Cisplatin or carboplatin, that is the question]. Bull Cancer98: 164–175.
- Mylonaki-Charalambours E, Mourelatos D, Kotsis A. (1998). A comparative study of the cytogenetic and antineoplasmatic effects induced by carboplatin in combination with niacin in human lymphocytes in vitro and in Ehrlich ascites tumor cells in vivo. Chemotherapy44: 121–128.
- Pastor ML, Laffont CM, Gladieff L, Chatelut E, Concordet D. (2015). Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment. Pharm Res32: 654–664.
- Rjiba-Touati K, Ayed-Boussema I, Soualeh N, Achour A, Bacha H, Abid S. (2013). Antioxidant and antigenotoxic role of recombinant human erythropoeitin against alkylating agents: cisplatin and mitomycin C in cultured Vero cells. Exp Biol Med (Maywood)238: 943–950.
- Sasaki MS. (1980). Chromosome aberration formation and sister chromatid exchange in relation to DNA repair in human cells. Basic Life Sci15: 285–313.
- Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Suga J, Nakano H, Nakagawa K, Hong WS, et al. (1988). Cytogenetic effect of carboplatin on human lymphocytes. Cancer Chemother Pharmacol21: 203–207.